{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:34Z","timestamp":1791500014421,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013068","name":"Key Technologies Research and Development Program of Guangzhou","doi-asserted-by":"publisher","award":["2023B1111030004"],"award-info":[{"award-number":["2023B1111030004"]}],"id":[{"id":"10.13039\/501100013068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104275"],"award-info":[{"award-number":["82104275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373938"],"award-info":[{"award-number":["82373938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204585"],"award-info":[{"award-number":["82204585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2022YFF1202600"],"award-info":[{"award-number":["2022YFF1202600"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jpha.2024.101175","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T11:36:42Z","timestamp":1735385802000},"page":"101175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-839X","authenticated-orcid":false,"given":"Yifei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-8309","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-9952","authenticated-orcid":false,"given":"Xingxing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2024.101175_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2024.101175_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.jpha.2024.101175_bib3","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jpha.2024.101175_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jpha.2024.101175_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2024.101175_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jpha.2024.101175_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib10","doi-asserted-by":"crossref","first-page":"18082","DOI":"10.1021\/acs.jmedchem.1c01496","article-title":"Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2024.101175_bib11","doi-asserted-by":"crossref","first-page":"13029","DOI":"10.1021\/acs.jmedchem.2c00877","article-title":"Linker-dependent folding rationalizes PROTAC cell permeability","volume":"65","author":"Poongavanam","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2024.101175_bib12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jpha.2024.101175_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115403","article-title":"Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy","volume":"255","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jpha.2024.101175_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","article-title":"Systematic investigation of the permeability of androgen receptor PROTACs","volume":"11","author":"Scott","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jpha.2024.101175_bib15","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2024.101175_bib16","article-title":"Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2024.101175_bib17","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-432","article-title":"Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC\u00ae estrogen receptor degrader","volume":"83","author":"Teh","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2024.101175_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-3075","article-title":"Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC\u00ae estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models","volume":"83","author":"Teh","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2024.101175_bib19","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-PD13-08","article-title":"Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC\u00ae estrogen receptor degrader, in ER+\/HER2- locally advanced or metastatic breast cancer","volume":"82","author":"Hamilton","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2024.101175_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1122","article-title":"VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+\/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer","volume":"41","author":"Campone","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpha.2024.101175_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically based pharmacokinetics joined with in vitro\u2013in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2024.101175_bib23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1124\/dmd.106.010793","article-title":"Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes","volume":"34","author":"Lu","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpha.2024.101175_bib24","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/jps.23502","article-title":"Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data","volume":"102","author":"Poulin","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpha.2024.101175_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jpha.2024.101175_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jpha.2023.04.001","article-title":"Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics","volume":"13","author":"Jang","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpha.2024.101175_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpt.1183","article-title":"Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and physiologically based pharmacokinetic modeling approaches","volume":"104","author":"Guo","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2024.101175_bib30","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpha.2024.101175_bib31","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpha.2024.101175_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2024.101175_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.tiv.2006.06.003","article-title":"Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements","volume":"20","author":"Sohlenius-Sternbeck","year":"2006","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.jpha.2024.101175_bib34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00498254.2012.669080","article-title":"Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes","volume":"42","author":"Sohlenius-Sternbeck","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpha.2024.101175_bib35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpha.2024.101175_bib36","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1023\/A:1018917729477","article-title":"Dissolution modeling: factors affecting the dissolution rates of polydisperse powders","volume":"10","author":"Lu","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2024.101175_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","article-title":"Commentary: a physiological approach to hepatic drug clearance","volume":"18","author":"Wilkinson","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12070672","article-title":"Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool","volume":"12","author":"Cheng","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpha.2024.101175_bib39","unstructured":"Arvinas, Leading the way in targeted protein degradation therapeutics. https:\/\/ir.arvinas.com\/static-files\/0fb6b5b5-be22-4bd4-b656-e1fdd238c1c6."},{"key":"10.1016\/j.jpha.2024.101175_bib40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/dmd.124.001661","article-title":"Application of electro-activated dissociation fragmentation technique to identifying glucuronidation and oxidative metabolism sites of vepdegestrant by liquid chromatography-high resolution mass spectrometry","volume":"52","author":"He","year":"2024","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpha.2024.101175_bib41","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jpha.2024.101175_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jpha.2024.101175_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor. Target. Antitumor Ther."},{"key":"10.1016\/j.jpha.2024.101175_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/dmd.123.001429","article-title":"Recommendations on the use of multiple labels in human mass balance studies","volume":"52","author":"Cuyckens","year":"2024","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpha.2024.101175_bib45","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1002\/jps.23288","article-title":"Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs","volume":"101","author":"Poulin","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpha.2024.101175_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2012.03.019","article-title":"Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model","volume":"429","author":"Paix\u00e3o","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2024.101175_bib47","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s11095-005-8192-x","article-title":"The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids","volume":"22","author":"Persson","year":"2005","journal-title":"Pharm. Res."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177924002727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177924002727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:55:11Z","timestamp":1762599311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177924002727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2095177924002727"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2024.101175","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2024.101175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}],"article-number":"101175"}}